BiotechTube

Gebasaxturev + Pembrolizumab

Phase 1/2Terminated
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm Metastasis

Conditions

Neoplasm Metastasis

Trial Timeline

Oct 28, 2020 → Jul 25, 2023

NCT ID
NCT04521621

About Gebasaxturev + Pembrolizumab

Gebasaxturev + Pembrolizumab is a phase 1/2 stage product being developed by Merck for Neoplasm Metastasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04521621. Target conditions include Neoplasm Metastasis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04521621Phase 1/2Terminated

Competing Products

20 competing products in Neoplasm Metastasis

See all competitors
ProductCompanyStageHype Score
AB0024Gilead SciencesPhase 1
32
TTI-237PfizerPhase 1
32
852APfizerPhase 1
32
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
32
LY2780301Eli LillyPhase 1
33
PemetrexedEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 1/2
41
IMC-3C5Eli LillyPhase 1
33
LY3295668Eli LillyPhase 1/2
41
Abemaciclib + ClarithromycinEli LillyPhase 1
33
Abemaciclib + FulvestrantEli LillyPhase 2
52
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
41
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
33
LY2784544Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
enzastaurinEli LillyPhase 2
52
enzastaurin + gemcitabineEli LillyPhase 2
52
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85